BAM
KRYS icon

Belpointe Asset Management’s Krystal Biotech KRYS Stock Holding History

Belpointe Asset Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-50
Closed -$4K – 2087
2023
Q1 		$4K Buy
50
+9
+22% +$707 ﹤0.01% 3094
2022
Q4 		$3.25K Buy
+41
New +$3.04K ﹤0.01% 3086

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Belpointe Asset Management's KRYS Position: Q2 2023 in Review

Belpointe Asset Management sold out of Krystal Biotech (KRYS) in Q2 2023, closing a stake of 50 shares — an estimated $4K sold.

Belpointe Asset Management first reported a position in KRYS in Q4 2022 and held it in 2 quarters. The position peaked at $4K in Q1 2023. 183 funds tracked by Wall St. Rank hold KRYS as of Q2 2023.

  • Belpointe Asset Management reported no remaining Krystal Biotech position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 50 Krystal Biotech shares in Q2 2023, an estimated $4K.
  • Belpointe Asset Management first reported a position in Krystal Biotech in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Krystal Biotech position peaked at $4K in Q1 2023.
  • 183 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.